Clinical characteristics and prognosis analysis of patients with IgG4-related hepatobiliary-pancreatic disease
10.3760/cma.j.cn501113-20230828-00073
- VernacularTitle:免疫球蛋白G4相关肝胆胰疾病患者的临床特征与预后分析
- Author:
Yunwei DU
1
;
Chenyi JIANG
;
Qi MIAO
;
Xiao XIAO
;
Qixia WANG
;
Jing HUA
;
Min LIAN
;
Xiong MA
Author Information
1. 上海交通大学医学院附属仁济医院消化内科 上海市消化疾病研究所，上海 200001
- Keywords:
IgG4-related hepatobiliary-pancreatic disease;
IgG4-related sclerosing cholangitis;
Autoimmune pancreatitis;
Clinical characteristics;
Treatment;
Prognosis
- From:
Chinese Journal of Hepatology
2024;32(10):916-922
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore and analyze the clinical features of patients with immunoglobulin (Ig)G4-related hepatobiliary-pancreatic disease and the independent factors affecting the prognosis of IgG4-related sclerosing cholangitis (IgG4-SC).Methods:The clinical data of 179 adult cases diagnosed with IgG4-related hepato-pancreato-biliary disease in the Division of Gastroenterology and Hepatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine from January 2011 to December 2022 were retrospectively analyzed. Patients were divided into three groups: isolated IgG4-SC, IgG4-SC/type 1 autoimmune pancreatitis(type 1 AIP), and isolated AIP according to the clinical manifestations. Demographic characteristics, baseline biochemical immunological indexes, and imaging manifestations were analyzed. The treatment response rate and survival rate were compared. The COX proportional hazards model was used to analyze the independent factors related to prognosis.Results:The mean age of diagnosis of patients with IgG4-related hepatobiliary-pancreatic disease was 60.3±12.0 years. Males accounted for 74.9%, and the median follow-up time was 38 months. The 1-year clinical response rate of patients with isolated IgG4-SC was lower than that of IgG4-SC/AIP (67.9% vs. 91.7%, P=0.019), and the primary endpoint-free 5-year survival rate was significantly reduced (64.9% vs. 95.9%, P<0.001). COX regression analysis showed that having cirrhosis before treatment ( HR=6.708, P=0.004) and poor response after half a year of treatment ( HR=11.488, P=0.002) were independent risk factors associated with the occurrence of adverse events in hepatobiliary diseases among patients with IgG4-SC. Conclusions:The clinical response rate and survival rate of patients with isolated IgG4-SC are lower than those of patients with IgG4-SC/AIP. Patients with IgG4-SC who do not respond well at six months of treatment and who have progressed to cirrhosis before treatment are at significantly increased risk of adverse events.
